Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)
14.05
+0.16
(+1.19%)
Streaming Delayed Price
Updated: 10:06 AM EDT, Jun 11, 2025
Add to My Watchlist
All News about Arcutis Biotherapeutics, Inc. - Common stock![]() ![]() Via Benzinga
![]() ![]() ![]() Via Benzinga
![]() ![]()
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
November 13, 2024
Via GlobeNewswire
![]() ![]() ![]() ![]()
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
October 22, 2024
Via Benzinga
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]()
FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
July 10, 2024
Via Benzinga
Exposures
Product Safety
![]()
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms Of Service. |
|